Management of Malignant Pleural Effusion in the Outpatient Clinic Using an Implantable Access System

DOI Web Site 6 References

Bibliographic Information

Other Title
  • 難治性胸水を伴う癌性胸膜炎に対する植え込み型胸腔ポートを用いた外来通院治療の検討

Search this article

Description

Objective. We investigated the effectiveness of the management of a malignant pleural effusion and repeated intrapleural chemotherapy using an implantable access system (BardPort-Ti®). Methods. Seven patients with histologically proven malignant pleural effusion were enrolled in this study. Three patients had malignant pleural effusions caused by primary lung cancer, two colon cancer, one rectal cancer, and one malignant mesothelioma. The implantable access system was placed under local anesthesia, and then the intrapleural administration of carboplatin (50 mg per body), 5-FU (250 mg per body) was performed biweekly using this system in the outpatient clinic. When malignant pleural effusion increased, we performed drainage through the port. Results. In all cases, implantation of this system was performed without major complication, and pleural effusion was easily managed in the outpatient clinic. There was no treatment-related mortality, renal dysfunction, bone marrow suppression or infection due to administration of the anticancer drug. The median survival time of the seven cases was 468 days. The mean period of the outpatient clinic was 181 days. Conclusion. This method enabled us to control easily malignant pleural effusion, increasing patient's QOL, and is useful, safe, and can be expected to increase relatively long-term survival.<br>

Journal

  • Haigan

    Haigan 46 (6), 711-714, 2006

    The Japan Lung Cancer Society

References(6)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top